scPharmaceuticals Inc. (SCPH)

scPharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	17.63	13.59	0	0	0	0
Revenue Growth (YoY)	754.68%	-	-	-	-	-
Cost of Revenue	4.99	3.81	0	0	0	0
Gross Profit	12.64	9.78	0	0	0	0
Selling, General & Admin	59.92	53.37	20.62	9.78	11.78	8.27
Research & Development	12.42	11.81	15.53	16.04	18.15	24.63
Operating Expenses	72.34	65.18	36.16	25.82	29.93	32.91
Operating Income	-59.7	-55.4	-36.16	-25.82	-29.93	-32.91
Interest Expense / Income	8.26	8.12	3.3	2.58	2.59	1.77
Other Expense / Income	-10.25	-8.71	-2.62	-0.36	-0.31	-1.68
Pretax Income	-57.71	-54.81	-36.84	-28.03	-32.21	-33
Net Income	-57.71	-54.81	-36.84	-28.03	-32.21	-33
Shares Outstanding (Basic)	39	39	28	27	25	19
Shares Outstanding (Diluted)	39	39	28	27	25	19
Shares Change	3.05%	35.81%	3.68%	11.33%	32.09%	0.24%
EPS (Basic)	-1.48	-1.42	-1.30	-1.02	-1.31	-1.77
EPS (Diluted)	-1.48	-1.42	-1.30	-1.02	-1.31	-1.77
Free Cash Flow	-60.49	-59.28	-34.6	-27.16	-27.69	-30.44
Free Cash Flow Per Share	-1.55	-1.54	-1.22	-0.99	-1.13	-1.64
Gross Margin	71.69%	71.96%	-	-	-	-
Operating Margin	-338.58%	-407.53%	-	-	-	-
Profit Margin	-327.29%	-403.22%	-	-	-	-
Free Cash Flow Margin	-343.08%	-436.14%	-	-	-	-
EBITDA	-48.87	-46.06	-33.07	-25.02	-29.22	-30.87
EBITDA Margin	-277.18%	-338.86%	-	-	-	-
Depreciation & Amortization	0.57	0.63	0.47	0.44	0.4	0.36
EBIT	-49.45	-46.69	-33.54	-25.46	-29.62	-31.23
EBIT Margin	-280.43%	-343.46%	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).